References in periodicals archive ?
Resche, "Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement," European Journal of Nuclear Medicine, vol.
The most commonly used radiopharmaceuticals, both [beta]-emitters, initially approved in the US for treatment of bone metastases are Strontium-89 chloride or 89Sr (Metastron; GE Healthcare, Arlington Heights, IL) and Samarium-153 or 153Sm (Quadramet; EUSA Pharma, Oxford, UK).